Abstract |
It is an exciting time in the treatment of systemic mastocytosis. Major advances in the past 2 decades have helped to define the molecular abnormalities associated with this disease and to delineate pathways involved in its pathogenesis. This has directly translated into the development of novel targeted therapies. These therapies hold great promise to patients and health care providers that a "cure" for systemic mastocytosis may someday be obtainable.
|
Authors | Todd M Wilson, Dean D Metcalfe, Jamie Robyn |
Journal | Immunology and allergy clinics of North America
(Immunol Allergy Clin North Am)
Vol. 26
Issue 3
Pg. 549-73
(Aug 2006)
ISSN: 0889-8561 [Print] United States |
PMID | 16931293
(Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)
|
Chemical References |
- Antineoplastic Agents
- Inflammation Mediators
|
Topics |
- Antineoplastic Agents
(chemistry, therapeutic use)
- Counseling
- Humans
- Inflammation Mediators
(immunology)
- Mastocytosis, Systemic
(therapy)
- Patient Education as Topic
|